1. Introduction {#sec1}
===============

Coronary heart disease (CHD) is one of the leading causes of morbidity and death in the developed countries, and its prevalence is increasing rapidly in the developing countries \[[@B1]\]. CHD has become a major health burden in the world \[[@B2]\]. CHD is a type of complex disease caused by both environmental and genetic factors, as well as interactions among these factors \[[@B3]\]. CHD may lead to severe events, including sudden cardiac death (SCD) or acute myocardial infarction (AMI). CHD is heritable \[[@B4]--[@B6]\]. Although genetic factors are estimated to account for about 30--60% of the CHD risk \[[@B7], [@B8]\], the pathogenesis of CHD is still not fully understood.

Aberrant levels of blood lipids and glucose are risk factors of CHD \[[@B9], [@B10]\]. Elevated triglyceride (TG) levels were shown to be associated with increased risk of CHD and other cardiovascular events \[[@B11]\]. The *GCKR* locus is the strongest completely novel locus implicated in TG metabolism \[[@B12]\]. Interestingly, *GCKR* is also associated with the risk of cardiovascular disease \[[@B13]\].

Located on chromosome 2p23, *GCKR* gene consists of 19 exons and encodes a protein comprising 625 amino acids \[[@B14]\]. *GCKR* is a susceptibility gene for type 2 diabetes mellitus \[[@B15]\]. *GCKR* gene product inhibits glucokinase in liver and pancreatic islet cells by binding noncovalently to form an inactive complex with glucokinase and thus plays a pivotal role in glucose homeostasis \[[@B16], [@B17]\]. Recent genome-wide association studies (GWAS) have identified that *GCKR* is important for modulating serum TG \[[@B18]\] or fasting blood glucose levels. CHD risk is strongly and independently associated with aberrant glucose metabolism \[[@B19], [@B20]\]. Furthermore, animal studies have confirmed that perturbation of the GCKR metabolic pathways may increase serum TG concentrations \[[@B21], [@B22]\].

*GCKR* rs780093 (A/G) polymorphism is an intronic SNP. A recent study discovered that *GCKR* rs780093 was associated with TG levels in Europeans \[[@B15]\]. Since most studies have been conducted in Europeans, one goal of our study is to confirm the correlation of *GCKR* rs780093 polymorphism and TG levels in Han Chinese population.

In the present study, we collected 568 CHD individuals and 494 non-CHD controls from Ningbo in Eastern China and performed a case-control study to investigate the contribution of *GCKR* rs780093 polymorphism to the risk of CHD and TG levels in Han Chinese population.

2. Methods and Materials {#sec2}
========================

2.1. Sample Collection {#sec2.1}
----------------------

A total of 1062 unrelated patients were recruited from the Ningbo Lihuili Hospital between September 2011 and May 2013. Our study consisted of 568 CHD cases (mean age: 61.66 ± 9.35) and 494 non-CHD controls (mean age: 57.96 ± 9.90). All patients were examined by standardized coronary artery angiographic according to Seldinger\'s method \[[@B23]\]. The diagnostic results were judged by at least two independent cardiologists. According to the angiographic results, CHD cases were defined as the diameter degree of stenosis ≥50% in any of the main coronary arteries. In addition, patients with a history of prior angioplasty or coronary artery bypass surgery were considered as CHD cases. Non-CHD controls had \<50% stenosis of any coronary artery or no history of the atherosclerotic vascular disease. The individuals with congenital heart disease or cardiomyopathy, liver, or kidney diseases were not included in the case or control groups. The blood samples were collected from the cases and controls in a fasting state and treated by the same investigators. Then, blood samples were collected in 3.2% citrate sodium-treated tubes and stored at  −80°C until analyzed. Serum triglycerides and total cholesterol were determined using an automatic analyzer (Hitachi 7060, Hitachi, Tokyo, Japan) within one month of sample collection. The study protocol was approved by the Ethics Committee of Lihuili Hospital in Ningbo. All participants signed the informed consent that included genetic association studies.

2.2. SNP Genotyping {#sec2.2}
-------------------

Genomic DNA was isolated from peripheral blood lymphocytes by the nucleic acid extraction automatic analyzer (Lab-Aid 820, Xiamen, China). DNA concentration was quantified using the PicoGreen double strand DNA Quantification Kit (Molecular Probes Inc., USA). PCR was performed on the GeneAmp PCR System, Veriti 96-well sample block module (Applied Biosystems, AB, USA). PCRs were set up as follows: 0.25 *μ*L in each of the three primers ([Table 1](#tab1){ref-type="table"}); 6 *μ*L SYBR Green I; 3.25 *μ*L ddH~2~O; and 2 *μ*L DNA. PCR procedure was set to start with an initial denaturation at 95°C for 30 sec, followed by 40 cycles of a three-step amplification, including denaturation at 95°C for 30 sec, 30 sec at 59°C for annealing, 30 sec at 72°C for primer extension, and a final extension for 30 sec at 72°C. Genotyping of the PCR products was performed using melting temperature shift (Tm shift) according to the manufacturer\'s instructions \[[@B24]\]. Tm-shift method uses two allele-specific primers and one reverse primer to amplify the polymorphic region encoding the targeted variant ([Figure 1](#fig1){ref-type="fig"} and [Table 1](#tab1){ref-type="table"}).

2.3. Statistical Analyses {#sec2.3}
-------------------------

Hardy-Weinberg equilibrium (HWE) was analyzed by the Arlequin program (version 3.5) \[[@B25]\]. Genotype distribution and allele frequencies between CHD cases and non-CHD controls were determined using Clump22 software with 10,000 Monte Carlo simulations \[[@B26]\]. Power analysis was performed using the Power and Sample Size Calculation Software \[[@B27]\]. The odds ratio (OR) and 95% confidence interval (CI) were assessed with an online program (<http://faculty.vassar.edu/lowry/odds2x2.html>). The logistic regression analysis was performed between genotype and degree of coronary stenosis using SAS statistical software. One-way ANOVA test was used to test the correlation between genotype and TG levels. Significant differences of all tests were indicated by values of *P* \< 0.05.

3. Results {#sec3}
==========

Baseline characteristics of the study populations were shown in [Table 2](#tab2){ref-type="table"}. Genotype distribution of rs780093 met HWE for both CHD cases and controls (*P* \> 0.05, [Table 3](#tab3){ref-type="table"}). Genotype and allele frequencies of *GCKR* rs780093 polymorphism were shown in [Table 3](#tab3){ref-type="table"}. [Figure 2](#fig2){ref-type="fig"} demonstrated the three genotypes (AA, AG, and GG) of *GCKR* rs780093 polymorphism by Tm-shift analysis. Our results showed that rs780093 was not associated with CHD in the whole samples ([Table 3](#tab3){ref-type="table"}), the gender-stratified samples ([Table 4](#tab4){ref-type="table"}). Association under the dominant and recessive models was also unable to present a significant association of rs780093 with CHD ([Table 5](#tab5){ref-type="table"}). Recent study in American population has shown that senior individuals (≥65 years of age) are eligible for secondary prevention of CHD \[[@B28]\]. Since age is an immutable risk factor of CHD, we performed an age-stratified analysis to study whether age influences the contribution of rs780093 to the risk of CHD. As shown in [Table 6](#tab6){ref-type="table"}, our subgroup analysis by age indicated a significant association between rs780093 and CHD among individuals aged 65 or older (genotype: *χ*^2^= 6.86; df = 2; *P* = 0.03; allele: OR = 1.38; 95% CI = 1.01--1.89; *χ*^2^ = 4.11; df = 1; *P* = 0.04).

Our study did not observe a gender difference for the association of rs780093 with CHD (*P* \> 0.05). A further genetic test under the dominant and recessive genetic models did not yield a significant result. A further subgroup analysis by age showed a significant association of rs780093 with CHD in the senior individuals (over 65 years old) under the dominant model ([Table 7](#tab7){ref-type="table"}, *P* = 0.01, OR = 2.03, and 95% CI = 1.26--3.27).

According to the angiographic results, we defined the severity of CHD into three stages, including one, two, and three or more coronary arteries with ≥50% stenosis. Logistic regression analysis showed no significant association between the stages of coronary artery stenosis and rs780093 ([Table 8](#tab8){ref-type="table"}).

In light of previous association between TG concentrations and rs780093 in European populations, we performed a similar correlation test in Han Chinese population. Our data confirmed that rs780093-AA genotype predicted a much higher TG level than other genotypes in Han Chinese population (*P* = 0.0016, [Figure 2](#fig2){ref-type="fig"}).

4. Discussion {#sec4}
=============

Our case-control study is aimed to explore the contribution of rs780093 to both the risk of CHD and TG level in Han Chinese population. Previous studies have demonstrated that the levels of TG and low-density lipoprotein cholesterol were independent heritable risk factors for cardiovascular diseases \[[@B29]\]. Some of the risk genes for CHD may influence their function by regulating or interacting with these factors. TG is composed of glycerol and fatty acids; circulating levels of fatty acids had been linked to the risk of CHD \[[@B30], [@B31]\]. Previous meta-analysis has shown a strong association of rs780093 with the level of fatty acids in Europeans \[[@B32]\]. And rs780093 A/A genotype was associated with both elevated circulating levels of fatty acids \[[@B32]\] and higher TG levels in multiple populations including Europeans \[[@B15], [@B33]\], Americans \[[@B33]\], and African Americans \[[@B34]\]. Consistent with previous findings, our results revealed that rs780093 was significantly associated with TG in Han Chinese population. In *GCKR*, rs780093 is in strong linkage disequilibrium (LD) with rs1260326 (Pro446Leu) in both YRI (*r*^2^ = 0.65) and CEU HapMap populations (*r*^2^ = 0.93). A previous study in European-ancestry individuals showed that rs1260326 had been consistently associated with elevated triglycerides and reduced fasting plasma glucose and reduced fasting plasma glucose \[[@B35], [@B36]\]. P446L of *GCKR gene*had shown to reduce inhibitory activity toward glucokinase, which would be predicted to increase glycolytic level and production of malonyl-CoA, a key substrate for TG synthesis and *de novo* lipogenesis \[[@B36]\]. Future study is warranted to investigate whether *GCKR* variants are able to increase the availability of substrate for *de novo* lipogenesis.

Early-onset CHD is defined if there is acute coronary syndrome (myocardial infarction or unstable angina), a revascularization process, or a positive functional imaging study at or before the age of 50 years in men or 55 years in women \[[@B37]\]. Most CHD occurs in individuals aged over 65; only 5--10% of CHD occurs in younger patients \[[@B2]\]. Although we cannot observe a significant association between rs780093 of *GCKR* gene and early-onset CHD, there is a significant association of rs780093 with CHD patients after 65.

According to the angiographic results, CHD patients were simply divided into three subgroups by the number of coronary arteries with stenosis. This classification method of CHD might not accurately reflect the severity of CHD, since the percentage of stenosis is not taken into account for the severity scale. This limitation in the classification may lead to a lack of correlation between rs780093 and the severity of CHD. A better parameter is needed to define the extent of coronary artery stenosis.

In the present study, the allele frequency of G (47.8%) is similar with that in HapMap CHB population (42.9%). We also observed a large ethnic difference of rs780093 in European (60.6%), Sub-Saharan African (89.8%), and Chinese population (47.8%) according to rs780093 frequency report in the HapMap project database. Although a total of 1062 individuals were recruited in the present study, our association of rs780093 has a 55% power, suggesting that our sample size may be not enough. Meanwhile, all the *P* values in the case-control study are not corrected by the number of tests; thus, we cannot exclude the possibility of false positive results in our findings.

In summary, *GCKR* rs780093 was significantly associated with the risk of CHD in Han Chinese population aged 65 or older and significantly lower TG levels. In addition, we observed the significant association between rs780093 and CHD after the age of 65 under the dominant model.
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###### 

Genotyping primers^a^.

  SNP        Primer type                        Primer sequence
  ---------- ---------------------------------- ----------------------------------------
  rs780093   GCKR-gF                            5′-gcgggcagggcggcCCCAAGCAAGAGCCCCCg-3′
  GCKR-aF    5′-gattaccgCCCAAGCAAGAGCCCCCa-3′   
  GCKR-R     5′-CCTGTCCTGTGGTTCTTGCAAATGC-3′    

^a^GCKR-gF and GCKR-aF stand for g and a allele-specific primers, respectively. GCKR-R denotes reverse primer.

###### 

Patients\' main clinical characteristics^a^.

  Characteristics          Cases (*n* = 568)   Controls (*n* = 494)
  ------------------------ ------------------- ----------------------
  Men (%)                  405 (71.3)          270 (54.7)
  Age (years, mean ± SD)   61.66 ± 9.35        57.96 ± 9.90
  TC (mmol/L)              4.28 ± 1.13         4.33 ± 0.98
  TG (mmol/L)              1.68 ± 1.08         1.57 ± 0.96

^a^TC stands for total cholesterol; TG denotes triglycerides.

###### 

Genotype distribution and allele frequencies of rs780093 in cases and controls^a^.

  rs780093               Genotype (counts)   *χ* ^2^   *P* (df = 2)   HWE    Allele (counts)   *χ* ^2^   *P* (df = 1)   OR (95% CI)                 
  ---------------------- ------------------- --------- -------------- ------ ----------------- --------- -------------- ------------- ------ ------ -------------------
  Cases (*n* = 568)      125                 297       146                                     0.28      547            589                          
  Controls (*n* = 494)   109                 252       133            0.23   0.89              0.65      470            518           0.07   0.79   1.02 (0.86--1.21)

^a^HWE: Hardy-Weinberg equilibrium; OR: odds ratio; CI: confidence interval.

###### 

A breakdown association test between cases and controls by gender^a^.

  Gender                 rs780093           Genotype (counts)   *χ* ^2^   *P* (df = 2)   HWE    Allele (counts)   *χ* ^2^   *P* (df = 1)   OR (95% CI)                              
  ---------------------- ------------------ ------------------- --------- -------------- ------ ----------------- --------- -------------- ------------- ------ ------------------- ---
  Male                   Case (*N* = 405)   93                  211       101                                     0.43      397            413                                       
  Controls (*N* = 270)   63                 138                 69        0.06           0.97   0.81              264       276            0.00          0.96   1.01 (0.81--1.25)   
  Female                 Case (*N* = 163)   32                  86        45                                      0.53      150            176                                       
  Controls (*N* = 224)   46                 114                 64        0.13           0.94   0.79              206       242            0.00          0.99   1.00 (0.75--1.33)   

^a^HWE: Hardy-Weinberg equilibrium; OR: odds ratio; CI: confidence interval.

###### 

Association of rs780093 with CHD under the dominant and recessive models^a^.

  rs780093   Dominant   *χ* ^2^   *P* (df = 1)   OR (95% CI)   Recessive           *χ* ^2^   *P* (df = 1)   OR (95% CI)          
  ---------- ---------- --------- -------------- ------------- ------------------- --------- -------------- ------------- ------ -------------------
  Cases      422        146                                                        125       443                                  
  Controls   361        133       0.20           0.65          1.06 (0.81--1.40)   109       385            0.00          0.98   1.00 (0.75--1.33)

^a^OR: odds ratio; CI: confidence interval.

###### 

A breakdown association test between cases and controls by age^a^.

  Age                    rs780093            Genotype (counts)   *χ* ^2^   *P* (df = 2)   HWE    Allele (counts)   *χ* ^2^   *P* (df = 1)   OR (95% CI)                              
  ---------------------- ------------------- ------------------- --------- -------------- ------ ----------------- --------- -------------- ------------- ------ ------------------- ---
  ≤55                    Cases (*n* = 138)   25                  73        40                                      0.49      123            153                                       
  Controls (*n* = 186)   44                  100                 42        2.44           0.30   0.38              188       184            2.26          0.13   0.79 (0.58--1.08)   
  55--65                 Cases (*n* = 200)   52                  94        54                                      0.40      198            202                                       
  Controls (*n* = 187)   43                  96                  48        0.79           0.67   0.77              182       192            0.05          0.82   1.03 (0.78--1.37)   
  ≥65                    Cases (*n* = 231)   49                  130       52                                      0.07      228            234                                       
  Controls (*n* = 121)   22                  56                  43        6.86           0.03   0.71              100       142            4.11          0.04   1.38 (1.01--1.89)   

^a^HWE: Hardy-Weinberg equilibrium; OR: odds ratio; CI: confidence interval.

###### 

A breakdown association of rs780093 with CHD by age under the dominant and recessive models^a^.

  Age                    rs780093           Dominant   *χ* ^2^   *P* (df = 1)   OR (95% CI)         Recessive   *χ* ^2^   *P* (df = 1)   OR (95% CI)                       
  ---------------------- ------------------ ---------- --------- -------------- ------------------- ----------- --------- -------------- ------------- ------------------- ---
  ≤55                    Case (*N* = 138)   98         40                                                       25        113                                               
  Controls (*N* = 186)   144                42         1.72      0.19           0.71 (0.43--1.18)   44          142       1.45           0.23          0.71 (0.41--1.24)   
  55--65                 Case (*N* = 200)   146        54                                                       52        148                                               
  Controls (*N* = 187)   139                48         0.08      0.77           0.93 (0.59--1.47)   43          144       0.47           0.49          1.18 (0.74--1.87)   
  ≥65                    Case (*N* = 231)   179        52                                                       49        182                                               
  Controls (*N* = 121)   78                 43         6.84      0.01           2.03 (1.26--3.27)   22          99        0.45           0.50          1.21 (0.69--2.12)   

^a^OR: odds ratio; CI: confidence interval.

###### 

Logistic regression analysis between rs780093 and the severity of CHD.

           Non-CHD controls   One affected artery   Two affected arteries   ≥Three affected arteries   Association with rs780093 (*P* value)
  -------- ------------------ --------------------- ----------------------- -------------------------- ---------------------------------------
  Male     270                154                   111                     137                        0.98
  Female   224                83                    36                      40                         0.47
  Total    **494**            **237**               **147**                 **177**                    **0.74**
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